| Filed | Form | Description | |
|---|---|---|---|
| 10/20/25 | DEFA14A | DEFA14A | → |
| 10/15/25 | DEF 14A | DEF 14A | → |
| 10/3/25 | PRE 14A | OTHER PRELIMINARY PROXY STATEMENTS | → |
| 3/11/25 | DEFA14A | DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | → |
| 3/11/25 | DEF 14A | DEFINITIVE PROXY STATEMENT | → |
| 3/21/24 | DEFA14A | MODERNA, INC. - DEFA14A | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 3/6/26 | 4 | PRIMARY DOCUMENT | → |
| 3/6/26 | 4 | PRIMARY DOCUMENT | → |
| 3/3/26 | 4 | PRIMARY DOCUMENT | → |
| 3/3/26 | 4 | PRIMARY DOCUMENT | → |
| 3/3/26 | 4 | PRIMARY DOCUMENT | → |
| 3/3/26 | 4 | PRIMARY DOCUMENT | → |
| ↓ | |||
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines.